Sustained release naltrexone effective, safe for opioid users

November 1, 2012
Sustained release naltrexone effective, safe for opioid users
Sustained release technologies for administering the opioid antagonist naltrexone seem to be effective with an acceptable adverse event profile, according to a review published online Oct. 22 in the British Journal of Clinical Pharmacology.

(HealthDay)—Sustained release technologies for administering the opioid antagonist naltrexone (SRX) seem to be effective with an acceptable adverse event profile, according to a review published online Oct. 22 in the British Journal of Clinical Pharmacology.

Nikolaj Kunøe, Ph.D., from the University of Oslo in Norway, and colleagues conducted a qualitative review of the literature to provide an overview of the currently available technologies for SRX and their effectiveness in reducing opioid use.

The researchers found that the most frequently studied SRX formulations have tolerable adverse event profiles and that most studies suggest that SRX is effective at decreasing heroin use. SRX may have a protective effect on mortality and morbidity, based on registry data. In some studies, other outcomes, including concomitant substance use, vocational training attendance, needle use, and risk behavior for blood-borne diseases (including HIV and hepatitis), were also affected by SRX.

"SRX is showing promising, consistent effects in supporting ' efforts to achieve abstinence across different clinical study design and treatment settings," the authors write. "The literature on SRX for opioid addiction still requires more studies in order to confirm initial findings on effects."

One author disclosed a financial tie to Go Medical Industries, which manufactures the Australian implant.

Explore further: Cardiac muscle really knows how to relax: Potential cardio-protective mechanism in heart

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Cardiac muscle really knows how to relax: Potential cardio-protective mechanism in heart

April 19, 2011
New insight into the physiology of cardiac muscle may lead to the development of therapeutic strategies that exploit an inherent protective state of the heart. The research, published by Cell Press online on April 19th in ...

Study sheds light on pain pill abuse

September 26, 2012
A study by a team of University of Kentucky researchers has shed new light on the potential habit-forming properties of the popular pain medication tramadol, in research funded by the National Institute on Drug Abuse. The ...

Polymorphism in opioid gene affects breast cancer survival

March 30, 2012
(HealthDay) -- Genotype at the A118G polymorphism of the µ-opioid receptor gene is associated with breast cancer-specific mortality, according to a study published in the April issue of Anesthesiology.

Recommended for you

Drug for spinal muscular atrophy prompts ethical dilemmas, bioethicists say

December 11, 2017
When the Food and Drug Administration approved the first drug for people with spinal muscular atrophy a year ago, clinicians finally had hope for improving the lives of patients with the rare debilitating muscular disease. ...

FDA's program to speed up drug approval shaved nearly a year off the process

December 7, 2017
Speeding the pace at which potentially lifesaving drugs are brought to market was a rallying cry for Donald Trump as a candidate, and is a stated priority of his Food and Drug Administration commissioner, Dr. Scott Gottlieb. ...

Dangers of commonly prescribed painkillers highlighted in study

December 6, 2017
Commonly prescribed painkillers need to be given for shorter periods of time to reduce the risk of obesity and sleep deprivation, a new study has revealed.

Viagra goes generic: Pfizer to launch own little white pill

December 6, 2017
The little blue pill that's helped millions of men in the bedroom is turning white. Drugmaker Pfizer is launching its own cheaper generic version of Viagra rather than lose most sales when the impotence pill gets its first ...

Surgery-related opioid doses can drop dramatically without affecting patients' pain

December 6, 2017
Some surgeons might be able to prescribe a third of opioid painkiller pills that they currently give patients, and not affect their level of post-surgery pain control, a new study suggests.

Four-fold jump in deaths in opioid-driven hospitalizations

December 4, 2017
People who end up in the hospital due to an opioid-related condition are four times more likely to die now than they were in 2000, according to research led by Harvard Medical School and published in the December issue of ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.